Gastrointestinal Agents

• 

  Subject Areas on Research

  • 10-biomarker algorithm to identify irritable bowel syndrome. 
  • A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. 
  • A pressing situation. 
  • A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. 
  • A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. 
  • Abdominal migraine: prophylactic treatment and follow-up. 
  • Acute histologic effects of extraesophageal reflux on vocal fold healing. 
  • Advances in the nontransplant medical and surgical management of intestinal failure. 
  • Adverse drug events in high risk older outpatients. 
  • Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. 
  • Alvimopan Provides Additional Improvement in Outcomes and Cost Savings in Enhanced Recovery Colorectal Surgery. 
  • As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection. 
  • Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians. 
  • Bombesin inhibits alveolarization and promotes pulmonary fibrosis in newborn mice. 
  • Celecoxib (celebrex) increases canine lower esophageal sphincter pressure. 
  • Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. 
  • Colonic Crohn Disease After Cardiac Transplantation: Case Report and Literature Review. 
  • Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. 
  • Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. 
  • Covert hepatic encephalopathy: not as minimal as you might think. 
  • Current guidelines for dyspepsia management. 
  • Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. 
  • Dyspepsia. 
  • Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. 
  • Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. 
  • Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. 
  • Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. 
  • Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. 
  • Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. 
  • Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. 
  • Functional dyspepsia. 
  • Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. 
  • Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • IBS in 2010: advances in pathophysiology, diagnosis and treatment. 
  • Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. 
  • Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. 
  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. 
  • Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates. 
  • Initial management strategies for dyspepsia. 
  • Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. 
  • Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. 
  • Irritable bowel syndrome. 
  • Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. 
  • Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation. 
  • Medication prescribing practices for older prisoners in the Texas prison system. 
  • Menetrier's disease treated with octreotide long-acting release. 
  • Metoclopramide Reduces Fluoroscopy and Procedure Time during Gastrojejunostomy Tube Placement: A Placebo-Controlled Trial. 
  • Multiple endocrine neoplasia type 1 manifesting with chronic and persistent diarrhea. 
  • Osteoporosis piece of multi-morbidity puzzle in geriatric care. 
  • Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. 
  • Promotility agents for the treatment of ileus in adult surgical patients: A practice management guideline from the Eastern Association for the Surgery of Trauma. 
  • Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. 
  • Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. 
  • Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. 
  • Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. 
  • Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid. 
  • Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. 
  • Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. 
  • The Impact of Alvimopan on Return of Bowel Function After Major Spine Surgery - A Prospective, Randomized, Double-Blind Study. 
  • The Impact of Risk Factors of Chronic Pancreatitis on Secretin Pancreatic Function Testing: Results of a 20-Year Study. 
  • The role of GIP in α-cells and glucagon secretion. 
  • Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. 
  • Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. 
  • WITHDRAWN: Initial management strategies for dyspepsia.